about
Meningeal melanomatosis: a challenge for timely diagnosis.Paraneoplastic cerebellar degeneration associated with anti-ITPR1 antibodies.Facing contrast-enhancing gliomas: perfusion MRI in grade III and grade IV gliomas according to tumor area.Combined central and peripheral demyelination: Clinical features, diagnostic findings, and treatment.Herpes simplex encephalitis in glioma patients: a challenging diagnosis.Acute late-onset encephalopathy after radiotherapy: an unusual life-threatening complication.Initial clinical presentation of young children with N-methyl-d-aspartate receptor encephalitis.Episodic Memory Impairments in Primary Brain Tumor Patients.Early intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with onconeural antibodies.Antineoplastic agents exacerbating Charcot Marie Tooth disease: red flags to avoid permanent disability.CLIPPERS mimickers: relapsing brainstem encephalitis associated with anti-MOG antibodies.Late post-transplant anti-aquaporin-4 Ab-positive optic neuritis in a patient with AML.Current therapeutic approaches to diffuse grade II and III gliomas.Diffuse gliomas classified by 1p/19q co-deletion, TERT promoter and IDH mutation status are associated with specific genetic risk loci.Safety of treatment with nivolumab after ipilimumab-related meningoradiculitis and bilateral optic neuropathy.Lower motor neuron syndrome in a patient with HER2-positive metastatic breast cancer: A case report and review of the literatureBrain Metastases from Lung Cancer: Is MET an Actionable Target?Acute late-onset encephalopathy after radiotherapy: an unusual life-threatening complicationMotor neuron disease of paraneoplastic origin: a rare but treatable conditionFGFR1 actionable mutations, molecular specificities, and outcome of adult midline gliomasTranscriptomic immune profiling of ovarian cancers in paraneoplastic cerebellar degeneration associated with anti-Yo antibodiesDemyelinating polyradiculoneuritis in patients with multiple myeloma: the other side of bortezomib-induced neurotoxicityThe molecular landscape of glioma in patients with Neurofibromatosis 1Long-term outcomes in temporal lobe epilepsy with glutamate decarboxylase antibodiesGuillain-Barré Syndrome During Platinum-Based Chemotherapy: A Case Series and Review of the LiteratureNeuropathic pain, dysautonomia, and nerve hyperexcitability: Expanding the spectrum of LGI1 autoimmunityNeurological paraneoplastic syndromes: an updateThe clinical use of IDH1 and IDH2 mutations in gliomasIsolated seizures are a common early feature of paraneoplastic anti-GABAB receptor encephalitisStroke-like events after brain radiotherapy: a large series with long-term follow-upCNS inflammatory disorder after concurrent radiotherapy-temozolomide and nivolumab in a glioblastoma patient
P50
Q35026061-685AFFDF-273D-436A-B817-0E5698C60838Q37626028-76D5C952-090C-4CEF-BE97-C42A74CB0666Q37717802-738A406B-0E6A-45F9-9679-792514A5ADB4Q39901096-C542A055-7F0F-4922-A0E0-EA770EAF6050Q42213188-C25B5E65-B50B-4F80-BA37-BADD3C523C96Q44616966-60C08389-D955-4539-8B6A-A095FD41CA86Q47556695-CA40E3B7-9D51-4893-B762-3B9B85FC8870Q47878717-94F116D3-4F96-4E13-988F-CC9E478C3403Q48101286-4353BF5C-FFE8-4574-BAB0-F422147E2FF5Q48111780-B7227C95-D310-4DE0-9CEE-23C979A21C9DQ48196886-66997C40-2F83-4B07-B05E-228A2A5ECECFQ48207843-03061BA8-55BA-4AC3-82A2-8F57EF92B92FQ49317056-2F392C21-A796-43AB-BD66-624A65A625B2Q49827418-EF4176F0-D9D5-4C36-AB89-596D8DD62DCAQ51826454-6937BB8E-F4B1-40D2-BA40-BA948B1D8C0FQ57106742-EB576AC8-3D09-4CB3-A3DF-9BBC9C0F5F4FQ64099560-2EE8096D-CCFF-464C-81D1-3076421AFCABQ87509896-1B3A3B66-B780-4BD0-93E0-49456D4A1E00Q88564374-F99466A1-D056-4A0B-B987-709A0DFF591AQ88574028-F53AFFBD-1600-4833-8390-DDA415A3AD0DQ89094817-8E52DE4F-645F-439F-9586-100E8CA40A88Q89980146-1AB3FEA1-3708-4ECF-BE19-774EBCF65F3CQ90371443-9AFF9A47-FF04-40A7-BE2D-FD3F0FC2BD94Q90716392-3F9D47AD-3F51-4C5C-A77F-52383BB82111Q90730413-45BFECD0-2425-4658-B8F9-6A71BD880995Q90740587-D0160BE4-3237-4992-9CDB-EF9C1CA7D4C3Q91035825-37DDD2FE-6D3E-4CB9-91A3-BD16AB898E47Q93070836-596490F6-5E01-45B3-81BF-37AA88A8146DQ93258111-8B49C23C-2161-4410-A371-35E23E7DF414Q93338975-B0FAD644-51AD-4099-A31B-AB11A3868A41Q93370719-D1E2BA8A-CB38-4046-A22B-7579D750B7BC
P50
description
investigador
@es
researcher
@en
name
Giulia Berzero
@en
type
label
Giulia Berzero
@en
prefLabel
Giulia Berzero
@en
P31
P496
0000-0001-8798-9058